Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul-Dec;16(2):238-244.
doi: 10.4103/ajts.ajts_145_21. Epub 2022 May 26.

Platelet additive solution suspended apheresis platelets in a tertiary care hospital: A step toward universal single donor platelets

Mohit Chowdhry  1 , Soma Agrawal  1 , Bindu Prakash  1 , Uday Kumar Thakur  1 , Manoj Mishra  1
Affiliations

Platelet additive solution suspended apheresis platelets in a tertiary care hospital: A step toward universal single donor platelets

Mohit Chowdhry et al. Asian J Transfus Sci. 2022 Jul-Dec.

Abstract

Background: Transfusion of ABO-compatible single donor platelets (SDP) is preferable for better outcomes over group switchover SDP. The use of SDP containing ABO-incompatible plasma is associated with a risk of allergic and acute hemolytic transfusion reactions. Moreover, high titer O group donors SDP impose a further threat to patient safety. Platelet additive solution (PAS) is used worldwide for the storage of platelets which reduces plasma volume available in SDP. SSP + (Macopharma) is one such PAS which can provide improved availability, logistical management, decrease wastage, and improvement in patient safety. The aim of this study was to assess the feasibility of using PAS to obtain low titer SDP units which can be utilized across a larger patient population and to study quality control parameters of these units.

Materials and methods: The study was performed in the department of Transfusion Medicine from June 2017 to January 2018 after clearance from the Institutional Review Board. The study design comprised two cohorts (A and B). In cohort A, the temporal trend of in-vitro changes in the quality parameters was tested and analyzed for PAS modified and unmodified products on days 1, 5 and 7. In cohort B, the original plasma from the SDP donors of all blood group donors except the AB group was tested for antibody titers before (prepreparation) and after modification (postpreparation) by PAS.

Results: In cohort A, in the control group, there was a significant change in the mean platelet volume, potassium, and bicarbonate levels from day 1 to day 7, whereas no significant change in the biochemical parameters was noted in the study group where PAS was used. In cohort B, on comparing the anti-A and anti-B, before and after modification of SDP with PAS, there was a significant reduction in the median titers across all the groups studied.

Conclusion: PAS added SDP is an efficient strategy to reduce the ABO-antibody levels significantly. PAS added SDP also helps in the better inventory management of available groups.

Keywords: Modified platelets; platelet additive solution; solid state drive.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Study design
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Blood Safety and Availability. [Last accessed on 2021 Aug 10]. Available from: https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availa... .
    1. Dhingra N, Lloyd SE, Fordham J, Amin NA. Challenges in global blood safety. World Hosp Health Serv. 2004;40:45–9. 51, 52. - PubMed
    1. Mathur A, Swamy N, Thapa S, Chakraborthy S, Jagannathan L. Adding to platelet safety and life: Platelet additive solutions. Asian J Transfus Sci. 2018;12:136–40. - PMC - PubMed
    1. Josephson CD, Castillejo MI, Grima K, Hillyer CD. ABO-mismatched platelet transfusions: Strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci. 2010;42:83–8. - PubMed
    1. Lozano M, Heddle N, Williamson LM, Wang G, AuBuchon JP, Dumont LJ, et al. Practices associated with ABO-incompatible platelet transfusions: A BEST Collaborative international survey. Transfusion. 2010;50:1743–8. - PubMed